Postmenopausal hormone therapy and atherosclerotic disease

Area of Science:

• Cardiovascular Science
• Endocrinology
• Women's Health

Background:

• Estrogen influences cardiovascular risk in women, with lower coronary heart disease (CHD) rates pre-menopause.
• A narrowing of the gender gap in CHD mortality occurs post-menopause.
• Bilateral oophorectomy in young women not treated with estrogen is linked to elevated CHD risk.

Purpose of the Study:

• To review evidence on estrogen's role in cardiovascular risk.
• To summarize observational data and proposed mechanisms of estrogen's cardioprotective effects.
• To highlight the need for randomized trial data to confirm clinical benefits.

Main Methods:

• Review of epidemiologic data on CHD rates in relation to menopausal status and estrogen use.
• Meta-analysis of observational studies comparing CHD risk in estrogen users versus nonusers.
• Examination of angiographic studies and physiological effects of estrogen on cardiovascular parameters.

Main Results:

• Over 30 observational studies suggest reduced CHD risk with estrogen replacement therapy (ERT).
• A meta-analysis indicated a 44% reduction in CHD risk among estrogen users.
• Estrogen favorably impacts lipid profiles, increasing HDL and decreasing LDL cholesterol, and may inhibit endothelial hyperplasia and low-density lipoprotein oxidation.

Conclusions:

• Observational data strongly suggest a cardioprotective role for estrogen replacement therapy in women.
• Estrogen exhibits favorable physiological effects on the cardiovascular system, including lipid metabolism.
• The definitive role of hormone replacement therapy in preventing clinical atherosclerotic events requires further investigation through randomized controlled trials.